Követés
Gennady Poda
Gennady Poda
PhD, Scientific Advisor & Group Leader, Computational Chemistry and Chemoinformatics, OICR
E-mail megerősítve itt: oicr.on.ca
Cím
Hivatkozott rá
Hivatkozott rá
Év
Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds
R Mannhold, GI Poda, C Ostermann, IV Tetko
Journal of pharmaceutical sciences 98 (3), 861-893, 2009
5922009
Can we estimate the accuracy of ADME–Tox predictions?
IV Tetko, P Bruneau, HW Mewes, DC Rohrer, GI Poda
Drug discovery today 11 (15-16), 700-707, 2006
2742006
Unleashing the therapeutic potential of human kallikrein-related serine proteases
I Prassas, A Eissa, G Poda, EP Diamandis
Nature reviews Drug discovery 14 (3), 183-202, 2015
2232015
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
F Grebien, M Vedadi, M Getlik, R Giambruno, A Grover, R Avellino, ...
Nature chemical biology 11 (8), 571-578, 2015
2192015
ToxAlerts: a web server of structural alerts for toxic chemicals and compounds with potential adverse reactions
I Sushko, E Salmina, VA Potemkin, G Poda, IV Tetko
Journal of chemical information and modeling 52 (8), 2310-2316, 2012
1862012
Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)
DR Anderson, MJ Meyers, WF Vernier, MW Mahoney, RG Kurumbail, ...
Journal of medicinal chemistry 50 (11), 2647-2654, 2007
1822007
Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds
IV Tetko, GI Poda
Journal of medicinal chemistry 47 (23), 5601-5604, 2004
1372004
Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
G Senisterra, H Wu, A Allali-Hassani, GA Wasney, D Barsyte-Lovejoy, ...
Biochemical Journal 449 (1), 151-159, 2013
1282013
Applications of neural networks in structure-activity relationships of a small number of molecules
IV Tetko, AI Luik, GI Poda
Journal of medicinal chemistry 36 (7), 811-814, 1993
1241993
Structure and mechanism of action of the hydroxy–aryl–aldehyde class of IRE1 endoribonuclease inhibitors
M Sanches, NM Duffy, M Talukdar, N Thevakumaran, D Chiovitti, ...
Nature communications 5 (1), 1-16, 2014
1112014
Molecular modelling of the ORL1 receptor and its complex with nociceptin.
CM Topham, L Moulédous, G Poda, B Maigret, JC Meunier
Protein engineering 11 (12), 1163-1179, 1998
921998
An Allosteric Inhibitor of Protein Arginine Methyltransferase 3
A Siarheyeva, G Senisterra, A Allali-Hassani, A Dong, E Dobrovetsky, ...
Structure, 2012
852012
A new, improved hybrid scoring function for molecular docking and scoring based on AutoDock and AutoDock Vina
VY Tanchuk, VO Tanin, AI Vovk, G Poda
Chemical biology & drug design 87 (4), 618-625, 2016
842016
Structure-based optimization of a small molecule antagonist of the interaction between WD repeat-containing protein 5 (WDR5) and mixed-lineage leukemia 1 (MLL1)
M Getlik, D Smil, C Zepeda-Velazquez, Y Bolshan, G Poda, H Wu, A Dong, ...
Journal of medicinal chemistry 59 (6), 2478-2496, 2016
692016
Condensation-driven assembly of boron-containing bis (heteroaryl) motifs using a linchpin approach
S Adachi, SK Liew, CF Lee, A Lough, Z He, JDS Denis, G Poda, AK Yudin
Organic letters 17 (22), 5594-5597, 2015
662015
Reconstitution and characterization of eukaryotic N6-threonylcarbamoylation of tRNA using a minimal enzyme system
LCK Wan, DYL Mao, D Neculai, J Strecker, D Chiovitti, I Kurinov, G Poda, ...
Nucleic acids research 41 (12), 6332-6346, 2013
622013
Benzothiophene inhibitors of MK2. Part 2: Improvements in kinase selectivity and cell potency
DR Anderson, MJ Meyers, RG Kurumbail, N Caspers, GI Poda, SA Long, ...
Bioorganic & Medicinal Chemistry Letters 19 (16), 4882-4884, 2009
622009
Promising Aedes aegypti repellent chemotypes identified through integrated QSAR, virtual screening, synthesis, and bioassay
PV Oliferenko, AA Oliferenko, GI Poda, DI Osolodkin, GG Pillai, ...
PLoS One 8 (9), e64547, 2013
562013
Synthesis, optimization, and evaluation of novel small molecules as antagonists of WDR5-MLL interaction
Y Bolshan, M Getlik, E Kuznetsova, GA Wasney, T Hajian, G Poda, ...
ACS medicinal chemistry letters 4 (3), 353-357, 2013
552013
HIV-1 reverse transcriptase inhibitor design using artificial neural networks
IV Tetko, VY Tanchuk, NP Chentsova, SV Antonenko, GI Poda, VP Kukhar, ...
Journal of Medicinal Chemistry 37 (16), 2520-2526, 1994
551994
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20